Sight Sciences, Inc. Forecasted to Post Q2 2022 Earnings of ($0.49) Per Share (NASDAQ:SGHT)

Sight Sciences, Inc. (NASDAQ:SGHTGet Rating) – Equities researchers at William Blair cut their Q2 2022 earnings per share (EPS) estimates for shares of Sight Sciences in a research note issued to investors on Wednesday, May 11th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of ($0.49) per share for the quarter, down from their previous forecast of ($0.44). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Sight Sciences’ Q3 2022 earnings at ($0.45) EPS, Q4 2022 earnings at ($0.43) EPS, FY2022 earnings at ($1.85) EPS, Q1 2023 earnings at ($0.43) EPS, Q2 2023 earnings at ($0.37) EPS, Q3 2023 earnings at ($0.36) EPS, Q4 2023 earnings at ($0.32) EPS and FY2023 earnings at ($1.49) EPS.

Sight Sciences (NASDAQ:SGHTGet Rating) last issued its earnings results on Thursday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.05. Sight Sciences had a negative return on equity of 51.67% and a negative net margin of 134.02%.

SGHT has been the topic of a number of other reports. Zacks Investment Research cut Sight Sciences from a “hold” rating to a “sell” rating in a report on Saturday. Piper Sandler decreased their target price on Sight Sciences from $23.00 to $17.00 in a report on Wednesday, May 11th. Finally, Citigroup decreased their target price on Sight Sciences from $39.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, March 25th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $28.40.

Shares of NASDAQ SGHT opened at $8.19 on Monday. The company has a quick ratio of 20.26, a current ratio of 21.28 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $389.76 million and a price-to-earnings ratio of -2.65. The stock’s fifty day simple moving average is $10.82 and its 200 day simple moving average is $15.74. Sight Sciences has a 52-week low of $6.25 and a 52-week high of $42.57.

Several hedge funds have recently modified their holdings of the company. KCK LTD. purchased a new position in shares of Sight Sciences during the fourth quarter valued at $83,918,000. Millennium Management LLC grew its holdings in shares of Sight Sciences by 1.0% during the fourth quarter. Millennium Management LLC now owns 1,592,615 shares of the company’s stock valued at $27,982,000 after buying an additional 15,523 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Sight Sciences during the third quarter valued at $32,070,000. Alliancebernstein L.P. grew its holdings in shares of Sight Sciences by 15.1% during the fourth quarter. Alliancebernstein L.P. now owns 1,435,936 shares of the company’s stock valued at $25,229,000 after buying an additional 188,179 shares in the last quarter. Finally, RTW Investments LP purchased a new position in Sight Sciences in the third quarter valued at about $29,144,000. Institutional investors and hedge funds own 60.76% of the company’s stock.

Sight Sciences Company Profile (Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

See Also

Earnings History and Estimates for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.